Seven & i Eyes Żabka Stake in Major European Expansion Push 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
SpaceX Eyes Pentagon AI Deal as Cloud Pricing Strategy Pressures CoreWeave 
PayPal Rejects $53 Billion Stripe-Advent Takeover Offer as Too Low: Report 
SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
Nationwide Data Center Protests Highlight Growing Backlash Against AI Expansion 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Volvo Cars Q2 Profit Falls as Automaker Bets on EX60 EV to Drive Recovery 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
GameStop Raises eBay Stake to 9.8% as Ryan Cohen Pushes $56 Billion Takeover Bid 
Mikron H1 2026 Sales Fall 5.9% as Automation Weakness Weighs on Profit 
NTSB Leads Investigation Into Ryanair Boeing 737 Engine Failure Over Greece 
Eisai Co., Ltd., a Japanese pharmaceutical company headquartered in Tokyo, Japan, is set to roll out its novel, Leqembi, developed to treat Alzheimer's disease. The company is expected to give the first doses to 1,500 patients in China on the launch of this new medical product.
Growth Prediction After Leqembi's Release
According to Reuters, Eisai will also experience massive growth once the Leqembi officially hits the market. The new drug for Alzheimer's disease will first be available for Chinese patients later this year.
The pharma company's spokesperson explained that it anticipates growth to speed up even more in 2025 because the disease's diagnosis also changes. Moreover, the representative said that more suitable Alzheimer's blood tests will also be ready, and this will further help the company reach a more significant share of the Chinese market, where an estimated 17 million people were diagnosed with an early stage of Alzheimer's.
"China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer's disease for Eisai," Eisai's spokesman stated. "The potential growth for Leqembi in China is huge."
Price and Eligibility
Eisai plans to release Leqembi in China and sell it for 200,000 yuan or around $28,180 annually. The company said it has not yet decided if it will ask for government coverage and will only do so after assessing the demand in the private market. If Eisai pushes through, it will be included on China's National Reimbursement Drug List, and prices could be reduced.
To be eligible for treatment with Eisai's Leqembi, patients must undergo cognitive and genetic testing to determine whether they have a gene that increases the drug's adverse side effects.
They must also go through testing to see if they have abnormal levels of amyloid. Once the treatment begins, all patients will still undergo a series of MRI scans to detect any potential fatal swelling and bleeding in the brain.
Approval of LEQEMBI By the FDA
The FDA approved Eisai's Leqembi in July 2023 to treat Alzheimer's Disease. According to the press release, it is the first and only approved treatment that has been able to lessen the rate of the disease's progression. The drug can also slow down cognitive and functional decline in adult patients.
Photo by: Eisai Website
